Advocate Outlines Resources for Chronic Myeloid Leukemia Population

Commentary
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.

In a conversation with CancerNetwork® at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Claire Saxton, MBA, described various resources that may offer guidance to patients with chronic myeloid leukemia (CML) as they receive treatment for their disease.

Saxton, the executive vice president of Insights and Impact at Cancer Support Community, listed a few patient advocacy organizations that can lend financial and mental health support to those who are undergoing therapy for CML. Beyond her organization, Saxton highlighted the Leukemia & Lymphoma Society and the CML Buster Foundation as groups that can assist patients with CML in the long term.

The Leukemia & Lymphoma Society aims to find a cure for leukemia, lymphoma, and multiple myeloma while improving patient quality of life through focus areas such as advancing health equity, improving clinical trial access, and offering patient financial assistance.1 This organization has initiated efforts to help increase federal research funds and expedite the review and approval process of new treatments for those with CML. Additionally, the CML Buster Foundation defines its purpose as an organization to “define, fund, create and maintain the tools of empowerment essential for the wellbeing of the [United States] CML community.”2

Transcript:

This is a long treatment journey. There is a huge impact [on the patient's] life, [their] family's life, and also on [their] mental health. Reach out for resources. It can be hard to find them initially, but there are a number of patient advocacy groups like Cancer Support Community, Leukemia & Lymphoma Society [LLS], and the [CML Buster Foundation] who are here and ready to help with financial counselors, support groups, and access to mental health professionals. Those are the kinds of things that are going to help give [them] the support that [they] need to get through [CML] in the long term.

References

  1. The LLS mission. Leukemia & Lymphoma Society. Accessed June 12, 2024. https://tinyurl.com/yck4hdjx
  2. CML Buster Foundation. GuideStar. Accessed June 12, 2024. https://tinyurl.com/yjx5y88h
Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content
Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

Forming International Collaborative Efforts to Assess Metformin Use in LFS

Russ Conroy
October 24th 2024
Article

Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.

Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer

Russ Conroy
October 17th 2024
Article

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

Darolutamide/ADT Improves rPFS in Metastatic HSPC

Jonah Feldman
October 13th 2024
Article

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.

Novel Allogenic CAR T Therapy Shows Responses in R/R Multiple Myeloma

Courtney Flaherty
October 12th 2024
Article

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.